PharmaCyte Biotech, Inc. financial data

Symbol
PMCB on Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
Location
23046 Avenida De La Carlota, Suite 600, Laguna Hills, California
State of incorporation
Nevada
Fiscal year end
April 30
Former names
NUVILEX, INC. (to 1/9/2015), EFOODSAFETY COM INC (to 3/17/2009)
Latest financial report
Q4 2023 - Mar 18, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 1.87K % -76.9%
Debt-to-equity 35.7 % +2935%
Return On Equity -2.53 % +62.3%
Return On Assets -1.5 % +77.3%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 8.46M shares -51.5%
Common Stock, Shares, Outstanding 8.52M shares -53.2%
Entity Public Float 54.2M USD -6.99%
Common Stock, Value, Issued 2.17K USD +0.32%
Weighted Average Number of Shares Outstanding, Basic 8.61M shares -54.7%
Weighted Average Number of Shares Outstanding, Diluted 8.61M shares -54.7%

Income Statement

Label TTM Value / Value Unit Change %
Revenues 0 USD
Research and Development Expense 399K USD -37.3%
General and Administrative Expense 2.21M USD +113%
Operating Income (Loss) -6.26M USD +11.4%
Nonoperating Income (Expense) 5.12M USD +254%
Income Tax Expense (Benefit) 0 USD
Net Income (Loss) Attributable to Parent -1.14M USD +79.7%
Earnings Per Share, Basic -1.21 USD/shares -548%
Earnings Per Share, Diluted -1.21 USD/shares -548%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 61.2M USD
Assets, Current 61.5M USD -15.5%
Intangible Assets, Net (Excluding Goodwill) 3.55M USD
Assets 71.4M USD -8.46%
Accounts Payable, Current 484K USD +8.58%
Employee-related Liabilities, Current 135K USD -9.39%
Accrued Liabilities, Current 774K USD +103%
Liabilities, Current 7.54M USD +811%
Liabilities 22.5M USD +2614%
Accumulated Other Comprehensive Income (Loss), Net of Tax -23.1K USD -30.2%
Retained Earnings (Accumulated Deficit) -117M USD -0.98%
Stockholders' Equity Attributable to Parent 31.4M USD -59.3%
Liabilities and Equity 71.4M USD -8.46%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities 343K USD
Net Cash Provided by (Used in) Financing Activities 6.28M USD
Net Cash Provided by (Used in) Investing Activities 0 USD
Common Stock, Shares Authorized 200M shares +500%
Common Stock, Shares, Issued 21.7M shares +0.32%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 6.62M USD
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 61.2M USD -15.7%
Interest Paid, Excluding Capitalized Interest, Operating Activities 0 USD -100%
Deferred Tax Assets, Valuation Allowance 16.2M USD +2.99%
Deferred Tax Assets, Gross 16.2M USD +2.99%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -1.46M USD +73.9%
Lessee, Operating Lease, Liability, to be Paid 1.16K USD -72.8%
Lessee, Operating Lease, Liability, to be Paid, Year Two 1.16K USD -43.6%
Deferred Tax Assets, Operating Loss Carryforwards 15.7M USD +3.92%
Preferred Stock, Shares Issued 35K shares
Preferred Stock, Shares Authorized 10M shares 0%
Additional Paid in Capital 189M USD -6.43%
Preferred Stock, Shares Outstanding 35K shares
Current State and Local Tax Expense (Benefit) -369K USD -1.81%
Deferred Tax Assets, Net of Valuation Allowance 0 USD
Interest Expense 0 USD -100%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%